CD70 CAR-T by UTC Therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CD70 CAR-T overview
Gene-modified cell therapy is under development for the treatment of renal cell carcinoma, glioblastoma, B-cell non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma, burkitt’s lymphoma, mantle cell lymphoma, anaplastic large cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia. The therapy comprises of T-cells that are genetically engineered to express chimeric antigen receptors (CARs) targeting cells expressing CD70 antigen (CD70). It is administered through parenteral route.
For a complete picture of CD70 CAR-T’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#CD70 #CART #UTC #Therapeutics #Refractory #Chronic #Lymphocytic #Leukemia #CLL #Likelihood #Approval
